GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

avizakimab   Click here for help

GtoPdb Ligand ID: 12270

Synonyms: BOS 161721 | BOS161721
Compound class: Antibody
Comment: Avizakimab (BOS161721; Boston Pharmaceuticals) is a humanized anti-IL-21 antibody that inhibits IL-21 bioactivity. It was developed for potential to treat systemic lupus erythematosus (SLE), an auotimmune condition in which IL-21 is implicated as a driving factor [3-5]. IL-21 has been explored as a therapeutic target in a range of autoimmune disease models (SLE, rheumatoid arthritis, type 1 diabetes and psoriasis). Peptide sequences for avizakimab are claimed in Boston Pharmaceuticals' patent US10022443B2 [1].
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11148 avizakimab
Synonyms Click here for help
BOS 161721 | BOS161721
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 941
Other databases
GtoPdb PubChem SID 473153858
Search PubMed clinical trials avizakimab
Search PubMed titles avizakimab
Search PubMed titles/abstracts avizakimab